NEU
Neuren Pharmaceuticals Limited
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
28
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Neuren Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment, and neurodegenerative disorders. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The Company’s lead drug compound, Trofinetide, is in Phase III clinical trial in the United States for Rett syndrome and has completed a Phase II clinical trial in Fragile X syndrome. The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted Orphan Drug designation to Neuren for trofinetide in Rett syndrome. The firm has granted an exclusive license to Acadia Pharmaceuticals Inc. for the development and commercialization of trofinetide in North America while retaining all rights outside North America. The firm is preparing to initiate Phase II trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.
📈 Performance
Price History
+2312.50%
1M
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$13.51
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in NEU
28
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in NEU
682 days
NEU investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
62%
Less than 50k
21%
👶 Age of investors
18 - 25
26 - 34
29%
35 - 90
68%
🙋 Legal gender of investors
Female
61%
Male
39%
Pearlers who invest in NEU also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
📊 Share price
$90.18 AUD
NULL AUSTRALIA
NULL BETA
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
📊 Share price
$104.08 AUD
NULL GLOBAL
NULL EX AUSTRALIA
NULL BETA
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
📊 Share price
$43.11 AUD
NULL US
NULL EX AUSTRALIA
NULL BETA
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
📊 Share price
$57.36 AUD
NULL GLOBAL
NULL SMART BETA
Core Lithium Ltd. is an Australian based mineral exploration company, which engages in the acquisition, exploration, evaluation, and development of copper, gold, uranium, and iron ore properties. The company is headquartered in Adelaide, South Australia. The company went IPO on 2011-02-11. The firm owns and operates Finniss Lithium project, which is located south of Darwin Port in the Northern Territory. The project lies within a prospective area for lithium in the NT, the Bynoe Pegmatite Field, and covers approximately 500 square kilometers (km2) of granted tenements. The project is approximately 88 kilometers (km) by sealed road from Darwin Port, Northern Territory. Its other projects include Shoobridge Lithium, Anningie and Barrow Creek Lithium, Sa Zinc, Jervois Domain, Blueys and Inkheart Lead/Silver, Bynoe Gold, Fitton Uranium, and Napperby Uranium. Shoobridge Lithium project is located approximately 80 km south-southeast of Finniss near Darwin in the Northern Territory. Sa Zinc project covers a total area of approximately 500 km2 in northern South Australia. Jervois Domain project covers three exploration licenses in the central Northern Territory.
📊 Share price
$1.07 AUD
Want more shares? Try these...